GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Captor Therapeutics CTX.WA · PLN

N/A · GPW · 🇵🇱 Poland

Compare

53.60

-0.74%

Close of 9 Nov 2026, in PLN

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Captor Therapeutics

Its shares trade on GPW under the ticker CTX.WA. It has been listed since 19 April 2021. In the fiscal year to 31 December 2025, it reported revenue of PLN 4.7m and a net loss of PLN 42.0m. At that date it held total assets of PLN 40.0m and shareholders' equity of PLN 23.5m.

Captor Therapeutics SA engages in the development of protein degradation drugs for cancer and autoimmune diseases. The company is headquartered in Wroclaw, Woj. Dolnoslaskie. The company went IPO on 2021-04-19. The firm works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The firm covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
19 Apr 2021
Employees
111

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Captor Therapeutics SA's Optigrade TM platform enables targeted protein degradation for cancer and autoimmune diseases.
  • The company focuses on unmet medical needs in neoplastic and autoimmune diseases with limited treatment options.
  • Captor Therapeutics SA has 111 full-time employees dedicated to early-stage drug development.

Weaknesses

  • Captor Therapeutics SA is headquartered in Wroclaw, Poland, which may limit access to global biotech hubs.
  • The company's IPO on 19 April 2021 indicates a relatively new market presence.
  • Captor Therapeutics SA operates in a highly competitive pharmaceutical sector with high R&D costs.

Opportunities

  • Expanding the Optigrade TM platform to address additional unmet medical needs in cancer and autoimmune diseases.
  • Collaborating with major pharmaceutical companies to leverage their distribution networks.
  • Growing demand for innovative treatments in the Health Care sector globally.

Threats

  • Regulatory challenges in the Health Care sector could delay drug approvals.
  • Competition from established pharmaceutical firms in the Information Technology-driven drug development space.
  • Economic downturns may reduce funding for biotech startups like Captor Therapeutics SA.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.